Revisions for Secukinumab for NLD (Cosentyx) in Patients With Necrobiosis Lipoidica Diabeticorum (NLD)
Primary tabs
| Revision | Operations |
|---|---|
| 12/29/2022 - 01:43 by Alicanto Admin | Current revision |
BIDMC Alicanto Learning Network
About Alicanto
Developed by the Division of Clinical Informatics at Beth Israel Deaconess Medical Center, Alicanto™ is an online collaboration platform for learning, group collaborations, and clinical care coordination used at Harvard hospitals. Learn more at Alicanto Cloud.
About DCI
Alicanto is developed by The Division of Clinical Informatics one of the first academic divisions in the world to concentrate on the use of computers for patient care, teaching, and medical research.
About BIDMC
DCI is part of Beth Isreal Deaconess Medical Cented a world-class teaching hospital of Harvard Medical School located in the heart of Boston.
Powered by Alicanto Cloud and Opigno